Does CBD get you high? The clear answer, from receptor to courtroom

The "high" from cannabis comes from THC, which activates a brain receptor called CB1. CBD does the opposite. A study published in the British Journal of Pharmacology in 2015 showed that cannabidiol is a negative allosteric modulator of the CB1 receptor: it reduces the potency and efficacy of THC and endocannabinoids at that receptor.

Put simply, where THC presses the accelerator, CBD eases off. That is the mechanism that explains why CBD does not cause intoxication. The difference is not one of degree but of nature — a point we develop in our article on the myths around CBD and THC.

This pharmacology is reflected in clinical observations. The WHO critical review report of 2018 states that CBD does not appear to have intoxicating effects and presents no potential for abuse or dependence, with no tolerance or withdrawal syndrome observed in animals or humans.

In the controlled studies cited, CBD does not produce any significant psychoactive effect. The subjective experience is therefore clearly distinct from THC intoxication: no euphoria, no altered perception.

The law has drawn the consequences of this science. In its Kanavape judgment of 19 November 2020, the Court of Justice of the European Union held that CBD "does not appear to have any psychotropic effect" and cannot be classified as a narcotic, with the result that a Member State cannot prohibit CBD lawfully produced in another.

In France, the Conseil d'État confirmed on 29 December 2022 that CBD "has no psychotropic effect and does not cause dependence" and "cannot be regarded as a narcotic product", annulling the ban on the sale of flowers and leaves. These formulations are quotations from court decisions, not commercial arguments.

What distinguishes a legal hemp product from illicit cannabis is its THC content. Legal products contain less than 0.3% THC, a level that the Conseil d'État found to be non-narcotic and distinguishable from illicit cannabis by rapid, inexpensive tests.

That threshold is the dividing line. Below it, the product falls under wellbeing hemp; above it, it switches to the narcotics regime. To clarify the often-confused vocabulary, see our articles hemp, cannabis, marijuana: what are the differences and weed, bud, CBD: what are we talking about.

A misunderstanding has been circulating since the withdrawal of ingestible CBD products on 15 May 2026. That measure falls under the Novel Food regulation, a food regulation — it is in no way a reclassification of CBD as a psychotropic or illegal product. The non-narcotic status of CBD, established by the CJEU in 2020 and the Conseil d'État in 2022, has not changed. Our update on CBD and Novel Food sets out the distinction.

Does CBD get you high?

No. CBD has no psychotropic effect. In the brain, it negatively modulates the CB1 receptor, unlike THC, which activates it. The WHO, the CJEU and the Conseil d'État have all established its lack of intoxicating effect.

Is CBD psychoactive?

CBD does not produce intoxication or euphoria comparable to THC. The WHO states that it does not appear to have intoxicating effects and presents no potential for abuse or dependence, with no tolerance or withdrawal observed.

What is the difference between CBD and THC?

THC activates the CB1 receptor and produces the high; CBD modulates it negatively and does not have that effect. A legal hemp product contains less than 0.3% THC, a threshold found to be non-narcotic by the Conseil d'État.

Is CBD considered a drug or a narcotic?

No. The Court of Justice of the European Union, in the 2020 Kanavape judgment, and the Conseil d'État, in December 2022, held that CBD is not a narcotic. The withdrawal of ingestible products in 2026 stems from a food rule, which is a separate question.